2 results
Approved WMOCompleted
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
Approved WMOCompleted
To assess the effect of Ziverel on esophageal sensitivity to acid, mucosal barrier function and reflux symptoms in patients with PPI-refractory reflux symptoms.